Skip to content
Human-limitedThymic peptide restoring immune vitality with age

Thymalin/Thymulin

Also indexed as Thymalin, Thymulin, FTS, Facteur Thymique Sérique, Serum Thymic Factor, Thymic Humoral Factor

Thymalin is a thymic peptide preparation derived from calf thymus glands, while Thymulin (FTS) is a naturally occurring nonapeptide produced by thymic epithelial cells that requires zinc as a cofactor for biological activity. Together they represent thymic-origin immunomodulatory compounds that restore and regulate T-lymphocyte differentiation, maturation, and function. They are used primarily to support immune system integrity, combat immunosenescence, and may have applications in anti-aging and recovery protocols.

Overview

Following subcutaneous or intramuscular administration, Thymalin distributes rapidly to lymphoid tissues including thymus remnants, spleen, and lymph nodes. Thymulin's short native half-life (~30 minutes) is compensated by downstream transcriptional effects that persist for days. It upregulates thymic output of naïve T-cells, restores T-cell receptor repertoire diversity (TCR Vβ diversity), and reduces senescent (p16+/p21+) immune cell burden. It also exhibits modulatory effects on the hypothalamic-pituitary-gonadal axis and has been shown to attenuate HPA axis hyperactivation in stress states.

Proposed mechanism

Thymulin binds to specific receptors on T-lymphocyte precursors in a zinc-dependent manner, promoting their differentiation into mature T-cell subsets (CD4+ and CD8+ cells) and modulating cytokine production including IL-2, IL-4, and interferon-gamma. It acts on the hypothalamic-pituitary-thyroid and neuroendocrine axes, influencing GnRH release and establishing bidirectional communication between the immune and endocrine systems. Thymalin, as a broader thymic extract, contains multiple bioactive peptides including thymulin that collectively upregulate innate and adaptive immunity by restoring thymic output and T-cell receptor signaling fidelity.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Peptide bioregulators and age-associated pathologies: clinical experience

    · Annals of the New York Academy of Sciences, vol. 1019 — Khavinson VKh et al. · 2003

  2. [2]

    Thymulin and zinc in aging

    · Gerontology, vol. 46(5) — Mocchegiani E, Muzzioli M · 2000

  3. [3]

    The neuroendocrine network: thymulin at the interface

    · Clinical Immunology and Immunopathology — Bach JF, Dardenne M · 1992

  4. [4]

    Immunological effects of thymic peptides in elderly patients

    · Bulletin of Experimental Biology and Medicine — Morozov VG, Khavinson VKh · 2006

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.